Genentech, OSI Ink $67M FCA Deal Over Cancer Drug Claims
Drugmakers Genentech and OSI Pharmaceuticals have agreed to pay $67 million to resolve allegations they violated the False Claims Act by making misleading statements about the effectiveness of cancer drug Tarceva,...To view the full article, register now.
Already a subscriber? Click here to view full article